A recent study showed increased efficacy of TKI, cabozantinib, or anti-PD-1 checkpoint-inhibition, when combined with an anti-IL-1β mAb in a heterotopic mouse model of RCC [255]. The gene discussed is PDCD1; the disease is renal cell carcinoma.